DNAe. The first true point-of-need Next Generation Sequencing company.

 

Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. To this end, we apply the best scientific skills and energy to build an evolving and innovative suite of electronic microchip-based solutions that delivers faster, simpler and more cost-effective DNA analysis.

And now, with LiDiaTM, comes the first point-of-need solution for rapid DNA analysis

Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. To this end, we apply the best scientific skills and energy to build an evolving and innovative suite of electronic microchip-based solutions that delivers faster, simpler and more cost-effective DNA analysis.

 

Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College, London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive genome centres into the mainstream of local labs and primary care clinics.

 

And now, with LiDiaTM, comes the first point-of-need solution for rapid DNA analysis.

 

Our company has grown to encompass the vast range of disciplines required to build molecular interfaces and assays on a semiconductor platform. Our core competencies in electronic engineering, molecular biology, fluidics and chemistry make us a force to be reckoned with. A force for good.

 

Headquartered in London, UK, and operating from Washington, DC, our company has expanded operations further in 2015 with a clinical diagnostic development and manufacturing site in San Diego, CA.

Our people

 

Management team

  • Professor Christofer Toumazou

    Executive Chairman

    Professor Christofer Toumazou‘s (FRS, FREng, FMedSci, FIET, FIEEE, FCGI, FRSM, CEng, DEng, PhD) dedication to bringing semiconductor solutions to healthcare is a long and accomplished one. He established himself as a respected scientist early in his career with the invention and development of entirely novel concept of current-mode analogue circuitry for ultra-low-power electronic devices for which he was made Professor at Imperial College at 33, one of the youngest in history. Since then he has gone on to publish over 700 research papers and holds over 50 patents in the field semiconductors and healthcare. He is also the Founding Director and Chief Scientist at The Institute of Biomedical Engineering Imperial College London; Founder of Toumaz Technology; Director of the Winston Wong Centre for Bio Inspired Technology, and Professor of Bio-Inspired Technology. His recent awards include: 2011 IET JJ Thomson Medal, 2009 World Technology Award, and the UK’s highest honour in science-Fellowship of the Royal Academy of Engineering and Fellowship of the Royal Society. In recognition of Chris’ invention of the semiconductor DNA sequencing technology he was awarded the Royal Society Gabor Medal (2013), won the 2014 European Inventor Award from the European Patent Office and the Institution of Engineering and Technology's highest accolade, the Faraday Medal (2014) along with the IEEE Biomedical Engineering Award for 2015 and 2016 The European Electronics Industry (ELEKTRA) Life Time Achievement Award.

  • Steve Allen

    Chief Executive Officer

    Steve Allen, Chief Executive Officer, joined DNAe in 2014. He is an experienced executive with a track record of growing a wide range of Life Science product and service companies, from start-ups to multinational corporations.  Before joining DNAe, Steve has held a number of leadership positions at PerkinElmer, Mettler-Toledo  and LGC Forensics. Having led the acquisition of over 15 companies and the successful launch of more than fifty new scientific products and services, Steve has used his experience to assist early stage companies to make the step change from scientific innovation to commercial success. This includes the Next Generation Sequencing startup Solexa, where he facilitated the development of the world’s leading whole genome analyzer, leading to the sale of the company to Illumina for $600 million.

  • Patrick Stephansen

    Chief Financial Officer

    Patrick Stephansen is a highly experienced investment and financial manager with over twenty-five years experience gained from London, Hong Kong and Oslo. His original qualification was in Economics and Business from the University of Brussels (Universite Libre de Bruxelles). Patrick’s experience spans Corporate Finance with Hambros Bank to senior management responsibilities at Mosvold Farsund Group- a substantial privately owned Norwegian investment and shipping group. The Group had numerous technology venture investments in Northern Europe and the US. From 2000 to 2004, he was the CEO of Glastad Capital following a restructuring of Mosvold Farsund. Currently he serves on the board of Toumaz Ltd, Lumi Mobile Ltd, SpineVision SA, and Tailwind Shipping Ltd.

  • Nick McCooke

    Chief Business Officer

    Nick is Chief Business Officer of DNA Electronics. He is an experienced and successful bio-entrepreneur, well-known for leading the Solexa team that built the Next Generation Sequencing(NGS) platform that became the basis of Illumina’s current market-leading product line.

    Previously, Nick was a consultant in the biotechnology industry, working primarily in the areas of NGS and biomarkers. In particular, he was recently interim COO of Cambridge Epigenetix, the Syncona-funded Cambridge University start-up, coordinating the launch, in August 2013, of their first product in the NGS space. Before that he was part-time CEO of Oxford Cancer Biomarkers for about 18 months from start-up, where he inked a key collaborative deal for the company with Astra Zeneca. thatEarlier he was CEO of Belgium-based Pronota nv, a company discovering novel protein biomarkers of disease in blood and developing them as diagnostic tests.

    He joined Solexa as CEO in 2000, and led it through the development of its game-changing DNA sequencing technology to its listing on NASDAQ.

    Apart from his base in the UK, Nick has lived and worked in the USA, Japan and Belgium. He is a non-executive director of AIM-listed biotech company Bioventix PLC and from June 2014, a trustee of the Association of Medical Research Charities. He has an MBA from the London Business School.

  • David Davidson

    Chief Scientific Officer

    David Davidson has served as our Chief Scientific Officer since November 2013. From May 2012 to October 2013, David led the Research and Development activities on our Point of Care project, leading to the launch of a rapid, simple-to-use skin-care genetic test with our partners, Geneonyx. David has more than 15 years of industry experience working in positions of increasing responsibility in biotechnology, drug discovery and diagnostics businesses. Previously, David served at SPD Development Company, a consumer diagnostics business headquartered in Geneva, Switzerland, which is a joint venture between Alere and Procter & Gamble, and prior to that at Millipore (previously known as Serologicals and Upstate Ltd before acquisition by Millipore) in their Drug Discovery Business Unit, and PPL Therapeutics plc, the transgenic technology company most noted for Dolly the Sheep. David received a B.Sc. in Immunology from the University of Glasgow and carried out post-graduate research in peptide vaccines and therapeutics prior to joining industry.

  • David Edington

    Vice President, R&D

    David Edington is a product developer with thirteen years of experience in the medical device industry. As VP, Research and Development at DNA Electronics he is responsible for translating the company’s core technology assets into a pipeline of successful products within a regulated environment. Before joining DNAe, David led the development and commercialisation of a variety of medical devices at PA Consulting Group’s laboratories in Cambridge, UK. He focuses on devices for Point of Care Testing (POCT) and has delivered successful product development programmes for US and EU diagnostics companies. David was a founder member of Exacsys Ltd, a POCT spin-out from PA Consulting Group, and has extensive experience of working with clinicians to translate unmet clinical needs into technically and commercially viable products. David’s PhD research involved the development of optical analytical instruments for the study of molecular liquids and model biological fluids.

  • Kevin Stearn

    Operations Director

    Kevin Stearn joined DNA Electronics in July 2014, he is a specialist in the manufacture and commercialisation of medical devices but his experience also spans electronics and engineering. As VP Operations at MediSense he played a pivotal role in building the production facilities which enabled MediSense to manufacture the world’s first commercial bio-sensor for diabetes monitoring. Over his 30 year career he has gained experience in a wide range of senior operational and commercial roles. Prior to joining Kevin was EMEA Business Development Director for KICTeam, running its European operation, MD of Alere’s UK and Chinese pregnancy test production facilities and MD of Diomed UK where he introduced a revolutionary new laser treatment, EVLT, to the European and Asia Pacific markets.

  • Victor Esch

    President and Chief Executive Officer - DNAe, Inc.

    Victor Esch has been CEO of nanoMR since 2008. Prior to this, he has successfully led product development in diverse organizations, start-ups, to large integrated programs.

    Victor was Director of Research and Development at Indigo Medical, responsible for all product development. Indigo was acquired by Johnson & Johnson in 1996. Following this he was CTO of EndoVasix, a company that produced an ischemic stroke treatment system. Endovasix was eventually acquired by W.L. Gore. He is a co-founder of PowerVision, a company successfully developing an accommodating intra-ocular lens to treat presbyopia. Victor has 30 issued patents and over 40 applications pending and his design innovations have been honored by R&D 100 and Photonics Circle of Excellence. He received his Ph.D. in Optical Sciences in 1990.

  • Sam Reed

    President, US Office

    Sam Reed is an experienced leader of New Product Development organisations and projects. From an educational background in Physics and Engineering, his primary experience has been in managing the translation of challenging novel technologies into successful products which meet peoples’ needs. He has led projects on behalf of clients (clients ranging from start-ups to Fortune 500 companies) and has also managed internal projects from the proof of concept to entrepreneurial exit and market success. From this background in project management, he has also set up people, processes, and organisations, to execute a portfolio such projects successfully. Past projects include medical devices, consumer products, and industrial products. In one relevant example from the past, he led development of a new detection technology into a handheld diagnostic medical device, which allowed users to take lab accuracy directly to the point of care. This project included phases from early technology development, user research and specification development, FDA 510(k),CLIA-waiver, license, and launch.

  • Jim Macemon,

    Chief Operating Officer - DNAe, Inc.

    Jim Macemon has more than 40 years of experience in Medical Device development and manufacturing spanning numerous product areas including diagnostics (chemistry and microbiology), critical care, patient monitoring, imaging, and lab products. He has led numerous R&D, Engineering, and Manufacturing teams, successfully launching products to aid laboratory and health care professionals and improve patient care.

    Jim received his undergraduate degree in engineering from Georgia Institute of Technology, followed by a Masters in Administrative Science from The Johns Hopkins University. During his career, he held senior positions with such companies as Baxter Healthcare, Richardson-Vicks, and SpaceLabs Medical, leading programs to develop laboratory and point-of-care diagnostic systems. Jim’s focus during the last 20 years has been with Venture Capital funded start-up companies developing revolutionary diagnostic and imaging technology. Most recently he was VP, Operations at Luminous Medical, leading the development, manufacturing and quality teams developing a patient-attached, real-time, glucose monitoring device with whole blood laboratory accuracy. He has 13 patents issued and several more pending.

  •  

    Board of directors

  • Tan Sri Lim Kok Thay

     

    Director Tan Sri Lim Kok Thay is the Chairman and Chief Executive of Genting Berhad, the holding company of the Genting Group. The Genting Group is one of Asia’s most dynamic conglomerates and is involved in leisure & hospitality, power generation, oil palm plantations, property development, biotechnology and oil & gas business activities. These business activities are undertaken by the Group’s key companies, namely Genting Malaysia Berhad, Genting Singapore Plc, Genting Hong Kong Limited, Genting Plantations Berhad and the Genting Energy division.

  • Professor Christofer Toumazou

     

    Professor Christofer Toumazou‘s (FRS, FREng, FIEEE, FIET, FRSM, FCGI, CEng, Deng, PhD) dedication to bringing semiconductor solutions to healthcare is a long and accomplished one. He established himself as a respected scientist early in his career with the invention and development of entirely novel concept of current-mode analogue circuitry for ultra-low-power electronic devices for which he was made Professor at Imperial College at 33, one of the youngest in history. Since then he has gone on to publish over 700 research papers and holds over 50 patents in the field semiconductors and healthcare. He is also the Founding Director and Chief Scientist at The Institute of Biomedical Engineering Imperial College London; Founder of Toumaz Technology; Director of the Winston Wong Centre for Bio Inspired Technology, and Professor of Bio-Inspired Technology. His recent awards include: 2011 IET JJ Thomson Medal, 2009 World Technology Award, and the UK’s highest honour in science-Fellowship of the Royal Academy of Engineering and Fellowship of the Royal Society. In recognition of Chris’ invention of the semiconductor DNA sequencing technology he was awarded the Royal Society Gabor Medal (2013), won the 2014 European Inventor Award from the EPO and the IET’s highest accolade, the Faraday Medal (2014) along with the IEEE Biomedical Engineering Award for 2015 and 2016 The European Electronics Industry (ELEKTRA) Life Time Achievement Award.

  • Steve Allen

     

    Steve Allen, Chief Executive Officer, joined DNAe in 2014. He is an experienced executive with a track record of growing a wide range of Life Science product and service companies, from start-ups to multinational corporations.  Before joining DNAe, Steve has held a number of leadership positions at PerkinElmer, Mettler-Toledo  and LGC Forensics. Having led the acquisition of over 15 companies and the successful launch of more than fifty new scientific products and services, Steve has used his experience to assist early stage companies to make the step change from scientific innovation to commercial success. This includes the Next Generation Sequencing startup Solexa, where he facilitated the development of the world’s leading whole genome analyzer, leading to the sale of the company to Illumina for $600 million.

  • Derrik Khoo Sin Huat

     

    Director Derrik Khoo Sin Huat was appointed as CEO of Asiatic Centre for Genome Technology (ACGT) Sdn Bhd, a Genting company on 1st February 2008. He is on secondment from Genting Berhad. Mr. Khoo leads a dynamic research and marketing team that is working to address global energy and environment challenges through ACGT’s partnership with Craig Venter’s Synthetic Genomics Inc. Prior to his appointment, Derrik was the Chief Innovation Officer of Genting Berhad between August 2006 and January 2008. Between May 2002 and August 2006, he was also Chief Operating Officer of eGENTING, the information communications technology (ICT) arm of Genting, . Derrik sits on the Genting Group Executive Committee and the Genting Plantations Berhad Executive Committee. He is a Director of Genting Genomics Limited, Edith Grove Limited and DNA Electronics Limited (DNAe). Derrik is also a three-term councillor of the Association of the Computer and Multimedia Industry of Malaysia (PIKOM), the National ICT Association of Malaysia.

  • Tan Kong Han

    Director Tan Kong Han was appointed as President and Chief Operating Officer of Genting Berhad in 2007. Genting Berhad is the holding company of the Genting Group which has over 58,000 employees, 4,500 hectares of prime resort land and about 133,000 hectares of plantation land. The Genting Group is one of Asia’s most dynamic conglomerates and is involved in leisure & hospitality, power generation, oil palm plantations, property development, biotechnology and oil & gas business activities. He was previously the Group Chief Operating Officer of Tanjong Public Limited Company which is an investment holding company of a group of subsidiaries involved in Power Generation, Leisure and Property Investment. Tan Kong Han also has more than 13 years working experience in investment banking and is a qualified Barrister at Law, Lincoln’s Inn. He holds a MA from the University of Cambridge.

  •  

    Clinical Advisory Board

  • Paul Dark, BSc, MBChB, PhD, FRCS, FRCEM, FFICM

    Chair in Critical Care Medicine, University of Manchester

    Professor of Critical Care Medicine & Honorary NHS Consultant, Salford Royal NHS Foundation Trust

    NIHR CRN National Research Lead for Critical Care, King’s College London, London, UK

    Paul Dark, BSc, MD, PhD, FRCS, FRCEM, FFICM, originally studied physics and then medicine. Graduating from The Manchester Medical School, he went on to study clinical academic surgery, emergency medicine and critical care at the Universities of Glasgow and Manchester in the UK, and at the Catholic University of Leuven, Belgium. He was a MRC Clinical Training Fellow, completing his PhD supervised by Professor Rod Little at the UK’s MRC Trauma Unit. Dr. Dark was appointed to his current clinical academic post at the University of Manchester in 2003, carrying out clinical duties in Critical Care Medicine at Salford Royal NHS Foundation Trust, one of the largest services in the UK. He holds senior academic leadership positions at the University of Manchester focused on developing postgraduate learning in research and innovation in acute healthcare. In addition, he leads a programme of work funded by the National Institute of Health Research (NIHR) developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe. Funded by Innovate UK (formerly Technology Strategy Board) Dr. Dark has led a programme of work developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and he leads multi-centre pragmatic clinical trials aimed at developing an improved evidence base for the management sepsis.

  • Angela Caliendo, MD, PhD, FIDSA

    Professor and Executive Vice Chair of the Department of Medicine

    Director of the Division of General Internal Medicine

    Alpert Medical School of Brown University, RI, USA

    Angela M. Caliendo, MD, PhD, FIDSA, is Professor, Executive Vice Chair of the Department of Medicine, and Director of the Division of General Internal Medicine at the Warren Alpert Medical School of Brown University.  Dr. Caliendo received a PhD (Biochemistry) and MD from Case Western Reserve University School of Medicine and completed an internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, MA and an Infectious Diseases fellowship at Massachusetts General Hospital, Boston MA.  Dr. Caliendo’s research has focused on the development of molecular diagnostic tests for the detection and quantification of infectious diseases and assessment of their clinical utility; molecular testing in transplantation; standardization of viral load testing; and evaluation of HIV-1 RNA burden and the development of antiretroviral resistance in HIV-1 seropositive women.  Dr. Caliendo is an Editor for the Journal of Clinical Microbiology, Chair of the Microbiology Medical Devices Panel for the FDA and was Chair of the Diagnostics Task Force for the Infectious Diseases Society of America and is currently on the Board of Directors for the Infectious Diseases Society of America.  She served as the President of the Association of Molecular Pathology (2004), President of the Pan-American Society for Clinical Virology (2010 -2012).  Dr. Caliendo has published over 135 peer-reviewed manuscripts covering various topics in clinical and diagnostic virology and microbiology and was a recent recipient of the Ed Nowakowski Senior Memorial Clinical Virology Award from the Pan American Society for Clinical Virology and the BD Award for Research in Clinical Microbiology from the American Society for Microbiology.

  • Stephan Harbarth, MD, MS

    Associate Professor of Medicine

    Associate Epidemiologist

    Senior Consultant in Infectious Diseases, Infection Control Programme

    Geneva University Hospitals and Faculty of Medicine, Geneva, CH

    Stephan Harbarth earned his medical degree from Ludwig-Maximilians-University in Munich in 1993 and completed his residency in internal medicine and tropical medicine at Munich University Hospitals. After serving as a clinical fellow in the Infectious Diseases Division and Infection Control Program in the Department of Internal Medicine at Geneva University Hospitals, Dr Harbarth completed his master’s degree in epidemiology at Harvard University in Boston. He is board certified in infectious diseases and was appointed associate professor at the University of Geneva in 2010. Dr Harbarth’s work has garnered several awards, including the ICAAC/ASM Young Investigator Award (2003), the Young Investigator Award from ESCMID (2006), the Swiss Society for Infectious Diseases Award for epidemiological research (2008, 2011), and the SHEA Investigator Award (2011). Dr Harbarth’s group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms. They participate in several ongoing large-scale EU-funded studies to address this public health threat and collaborate closely with the Genomics Research Laboratory at HUG, based on a productive translational research platform.

  • Romney Humphries, PhD, D(ABMM), M(ASCP)CM

    Assistant Professor, Pathology and Laboratory Medicine

    Section Chief of Clinical Microbiology

    David Geffen School of Medicine

    University of California, Los Angeles, CA, USA

    Romney M. Humphries, Ph.D., D(ABMM), is an Assistant Professor in the Department of Pathology and Laboratory Medicine in the David Geffen School of Medicine at the University of California, Los Angeles. She is the Section Chief for Clinical Microbiology at the UCLA Health and Chief Quality Officer for the Department of Pathology & Laboratory Medicine. Romney received her undergraduate degree in biochemistry from the University of Lethbridge, Canada. She completed her PhD in bacterial pathogenesis at the University of Calgary, Canada and a CPEP fellowship in Medical and Public Health Microbiology at the University of California, Los Angeles. Romney’s research focus is the detection and characterization of emerging antimicrobial resistance in bacteria, and the development of next generation diagnostic technologies. She is a member of the CLSI AST Subcommittee and Microbiology Resource Committee for the College of American Pathologists.

COMPANY DETAILS

 

Email: contact@dnae.com

Switchboard: +44 (0)20 7036 2100

Fax: +44 (0)20 7036 2144

Twitter: @dna_electronics

OFFICE  LOCATIONS

DNAe Group Holdings Ltd

Ugli Campus Block C

56 Wood Lane

London

W12 7SB

United Kingdom

 

Google map

DNA Electronics, Inc.

1891 Rutherford Road

Suite 100

Carlsbad, CA 92008

USA

+1 (760) 444-9410

 

Google map

KEEP IN TOUCH

Submitting Form...

The server encountered an error.

Thank you for joining our mailing list

© 2017 DNA Electronics    Privacy & Cookies | Terms of Use